COMMUNIQUÉS West-GlobeNewswire

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...
18/07/2017
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]
NICOX : Nombre de droits de vote au 17 juillet 2017
18/07/2017
Nicox SA Société anonyme au capital de 25 669 338 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 17 juillet 2017, PUBLICATION MENSUELLE DU NOMBRE D' [...]
NICOX : Number of voting rights as of July 17, 2017
18/07/2017
Number Nicox SA Société anonyme with a registered capital of € 25,669,338 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On July 17, 2017, MONTHLY PUBLICATION OF [...]
Summit Therapeutics plc : Result of AGM
18/07/2017
Summit Therapeutics plc ('Summit' or 'the Company') RESULT OF ANNUAL GENERAL MEETING Oxford, UK, 18 July 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing [...]
FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants
18/07/2017
FIT Biotech Oy Company release July 18, 2017 at 4:00 pm FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants On September 26, 2016, the Board of Directors of FIT Biotech Oy ( [...]
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody
18/07/2017
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody Shire obtains worldwide license to pursue development and commercialization of a novel, potentially [...]
Shire plc : Notice of Results
18/07/2017
Shire to announce second quarter 2017 results Dublin, Ireland - July 18, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), will announce second quarter 2017 earnings on Thursday August 3, 2017. Results press release will be [...]
Allergy Therapeutics: Trading Update
18/07/2017
Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Trading Update 15% constant currency revenue growth Double-digit compound annual revenue growth over the past 18 years 18 July 2017 Allergy Therapeutics [...]
Midatech Pharma Plc: Trading Update and Notice of Results
18/07/2017
18 July 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Trading Update and Notice of Results Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing [...]
uniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell-Based AAV Manufacturing
18/07/2017
Patent Covers Overlapping Rep78/52 Nucleotide Sequences for Robust, Large-Scale Production of AAV Constructs LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 18, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE [...]
Enzymatica recruits Chief Commercial Officer
18/07/2017
Press release Lund, 18 July 2017 Enzymatica recruits Chief Commercial Officer Enzymatica has recruited Claus Egstrand as its Chief Commercial Officer. Claus Egstrand's primary responsibility will be to develop [...]
CellaVision AB: Strong second quarter with growth and increased profitability
18/07/2017
Interim report January-June 2017 April 1-June 30, 2017 · Net sales increased by 20 % to SEK 78.7 million (65.7). · Organic growth for the quarter was 16% (27). · Operating profit increased by 29% to SEK 24.6 million (19 [...]
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
18/07/2017
Net sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications Entresto (USD 110 million) [...]
Les résultats du T2 confirment les prévisions de l'exercice 2017. Les très bons résultats du pipeline étayent le potentiel de plusieurs produits hautement novateurs
18/07/2017
Chiffre d'affaires net comparable à celui du T2 de l'exercice précédent (0% tcc[1], -2% en USD), car les moteurs de croissance ont compensé l'impact des génériques de Gleevec/Glivec : Cosentyx (USD 490 millions, +90% [...]
EDAP Announces Withdrawal of 510(k) Application for Focal One® to be Followed by New Submission to Conform to FDA Review Rules
17/07/2017
New 510(k) With New Clinical Data to be Submitted for Focal One® Initial 510(k) to be submitted for Ablatherm Fusion® LYON, France, July 17, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in [...]
Ossur Hf : Transactions in relation to share buyback program
17/07/2017
A nnouncement from Össur hf. No. 50/2017 Reykjavík, 17 July 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]
Sanofi : Disclosure of trading in own shares
17/07/2017
Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Sanofi : Déclaration des transactions sur actions propres
17/07/2017
Reporting FR This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Diaxonhit : mise en oeuvre du regroupement d'actions par 20 entre le 1er août et le 1er septembre 2017
17/07/2017
MISE EN OEUVRE DU REGROUPEMENT D'ACTIONS DIAXONHIT Regroupement d'actions par voie d'échange à raison de 1 action nouvelle regroupée contre 20 actions anciennes ; Début des opérations de regroupement : 1 er août 2017 ; [...]

Pages